Cargando…

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

BACKGROUND: Sorafenib and sunitinib are widely used as first-line targeted therapy for metastatic renal cell carcinoma (mRCC) in China. This study aimed to compare the efficacy, safety, and quality of life (QoL) in Chinese mRCC patients treated with sorafenib and sunitinib as first-line therapy. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Wen, Kong, Wen, Dong, Baijun, Zhang, Jin, Chen, Yonghui, Xue, Wei, Huang, Yiran, Zhou, Lixin, Huang, Jiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547674/ https://www.ncbi.nlm.nih.gov/pubmed/28789709 http://dx.doi.org/10.1186/s40880-017-0230-7

Ejemplares similares

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma
por: Cai, Wen, et al.
Publicado: (2017)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
por: Zhang, Hai-Liang, et al.
Publicado: (2017)

Comprehensive Genomic Landscape in Chinese Clear Cell Renal Cell Carcinoma Patients
por: Huang, Jiwei, et al.
Publicado: (2021)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2019)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
por: Randrup Hansen, Caroline, et al.
Publicado: (2017)

High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma
por: Wang, Jianfeng, et al.
Publicado: (2016)

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
por: Zhang, Hailiang, et al.
Publicado: (2009)

LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling
por: Zhu, Liangsong, et al.
Publicado: (2019)

VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas
por: Zhou, Jiale, et al.
Publicado: (2022)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

TIKI2 is upregulated and plays an oncogenic role in renal cell carcinoma
por: Yuan, Xiaodong, et al.
Publicado: (2016)

Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis
por: Liu, Xiu-Lan, et al.
Publicado: (2020)

Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Li, Dailong, et al.
Publicado: (2023)

Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody
por: Huang, Jiwei, et al.
Publicado: (2021)

Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer
por: Ma, Xin, et al.
Publicado: (2016)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Preoperative evaluation of renal artery in patients with renal tumor: Using noncontrast-enhanced magnetic resonance angiography
por: Zhu, Liangsong, et al.
Publicado: (2016)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Transitional cell carcinoma with extension of the renal vein and IVC tumor thrombus: report of three cases and literature review
por: Li, Mingyang, et al.
Publicado: (2016)

Pathologic analysis of non-neoplastic parenchyma in renal cell carcinoma: a comprehensive observation in radical nephrectomy specimens
por: Wang, Xun, et al.
Publicado: (2017)

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study
por: Ambring, Anneli, et al.
Publicado: (2012)

Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib
por: Niinivirta, Marjut, et al.
Publicado: (2017)

Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression
por: Xu, Yunze, et al.
Publicado: (2015)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
por: Sheng, Xinan, et al.
Publicado: (2020)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
por: Hwang, Eugene, et al.
Publicado: (2010)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
por: Czarnecka, Anna M., et al.
Publicado: (2019)

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
por: Badran, Ahmed, et al.
Publicado: (2020)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
por: Lin, Jingyang, et al.
Publicado: (2023)

AB186. The efficacy and safety of sorafenib in Chinese patients with metastatic renal cell carcinoma and prognostic factors related to its efficacy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Peritumoral Artery Scoring System: a Novel Scoring System to Predict Renal Function Outcome after Laparoscopic Partial Nephrectomy
por: Zhang, Ruiyun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7rleu1t3eipdkk65obob2lop8u